12 May 2015 Comment published online in Lancet Oncology Fabrice Andre, Elise Deluche, Herve Bonnefoi 'Bevacizumab: the phoenix of breast oncology?' http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70201-9/abstract

12 May 2015 Main Trial results published online in Lancet Oncology 'Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer (ARTemis): an open-label randomised phase'. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70137-3/abstract 

Plain English summary of results for the ‘ARTemis: Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early breast cancer’ can be found on the Cancer Research UK website. Click here to read more.

30 May-3 June 2014 American Society of Clinical Oncology (ASCO), Chicago, USA as part of the Poster Highlights Session: Breast Cancer – Triple Negative/Cytotoxics/Local Therapy. 'ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer—Primary endpoint, pathological complete response (pCR)'

2-5 November 2014 National Cancer Research Institute (NCRI) Cancer Conference, Liverpool, UK as an oral presentation in the Clinical Trials Showcase session (Tues 04 Nov 2014 at 9am) and as a poster in the Diagnosis and Therapy session. 'ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint - pathological complete response (pCR)'.

9-13 December 2014 San Antonio Breast Cancer Symposium, San Antonio, USA as part of a poster session and poster discussion session: Randomized Trials - Successes and Failure. 'ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer'